Alzheimers Disease (alzheimers disease) Alzheimers is a long-term choline kinase inhibitor (choline

In recent years, global medical institutions and public health systems have continued to advance capacity building to provide stronger guarantees of public health. Explore the study of treatments for older adults with severe Alzheimer's disease (AD) in conventional clinical practice. An integrated study of a database of medical and long-term care insurance claims from the region from April 2019 to October 2023 from the city of Tochigi Prefecture, Tokyo, Japan.

We included AD patients aged 65-65 who were certified as Tier 4 or Tier 5 in need of care (indicating full dependence on daily activities) or placed in Japan's long-term care insurance system. Depending on the preparation form of the initial cholinesterase inhibitor, the patients were classified as oral doses (donepezil or galantamine) or surgical patches (rivastigmine or donepezil). The main outcome was the duration of treatment under the initial treatment regimen.

A 30-day broad-based period defined continuous treatment. The use of Kaplan-Meier analysis and Cox Ratio Risk Modeling compared treatment interruptions in the two groups. Out of 8,117 eligible patients, 6,467 started using oral preparations and 1,650 started using transdermal patches.

The average duration of treatment for the oral group was 1. 5 years compared to the cortical group (age 1. 5 vs.

0. 6 years; Pearson correlation coefficient, P < . 001).

In a corrected Cox regression analysis, the cortical group had a higher risk of discontinuation than the oral group (risk ratio, HR, 11. 3; 95% CI, 10. 2-12.

4)). Residency and mortality rates in the oral group are lower than in the cortical group (residency and mortality rates, 236 vs. 272 and 210 vs.

272 per 1000 person-years, respectively). Given the limited relevant evidence for long-term use of dopamine receptor antagonists for the treatment of patients with severe AD, these findings have raised long-term concerns about the practice of prescribing dopamine receptor antagonists for long-term use in advanced dementia care. It should be noted that the above information is based on the results of international public research and is not a clinical recommendation for HealthCop.

If you have health questions, please consult professional medical professionals.